Day Gain | ||
Gain | ||
Market Val | ||
Costs | ||
Cash | ||
Portfolio | ||
Realized | ||
Dividend |
Better Dividend Stock: AbbVie or Johnson & Johnson? | fool.com • |
AbbVie Inc. (NYSE:ABBV) Shares Sold by Bahl & Gaynor Inc. | news.google.com • |
3 Dividend Stocks to Buy and Hold for the Next Decade | fool.com • |
ABBV Stock Earnings: AbbVie Beats EPS, Beats Revenue for Q1 2024 | news.google.com • |
AbbVie (NYSE:ABBV) Sinks as Humira Drug Sees Increased Competition- TipRanks | news.google.com • |
Abbvie stock falls amid growing biosimilar competition | news.google.com • |
Date | For | Estimate | Reported | Surprise | surprise % |
---|---|---|---|---|---|
2024-04-26 | 2024-03 | 2.26 | 2.31 | 0.05 | 2.21% |
2024-02-02 | 2023-12 | 2.76 | 2.79 | 0.03 | 1.09% |
2023-10-27 | 2023-09 | 2.86 | 2.95 | 0.09 | 3.15% |
2023-07-27 | 2023-06 | 2.79 | 2.91 | 0.12 | 4.30% |
2023-04-27 | 2023-03 | 2.44 | 2.46 | 0.02 | 0.82% |
2023-02-09 | 2022-12 | 3.54 | 3.6 | 0.06 | 1.69% |
Date | Firm | Action | From | To |
---|---|---|---|---|
2023-10-10 | Morgan Stanley | Upgrade | Overweight | Overweight |
2023-09-28 | Raymond James | Upgrade | Outperform | |
2023-07-27 | Piper Sandler | Upgrade | Overweight | Overweight |
2023-07-24 | William Blair | Upgrade | Market Perform | |
2023-07-13 | HSBC | Upgrade | Buy | |
2023-07-10 | Morgan Stanley | Upgrade | Overweight | Overweight |
Date | Name | Relation | Quantity | Description |
---|---|---|---|---|
2024-02-28 | BUCKBEE KEVIN K | Officer | 6.98K | Sale |
2024-03-19 | DONOGHOE NICHOLAS | Officer | 55.90K | Sale |
2024-02-27 | GONZALEZ RICHARD A | Chief Executive Officer | 519.10K | Sale |
2024-02-14 | HUDSON THOMAS J | Officer | 127.90K | Stock Award(Grant) |
2024-02-28 | MICHAEL ROBERT A. | President | 98.65K | Sale |
2024-02-22 | REENTS SCOTT T. | Chief Financial Officer | 15.43K | Sale |
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-06-29 | Vanguard Group Inc | 159.30M | 21.46B | 9.03% |
2023-06-29 | Blackrock Inc. | 139.16M | 18.75B | 7.88% |
2023-06-29 | State Street Corporation | 78.18M | 10.53B | 4.43% |
2023-06-29 | JP Morgan Chase & Company | 56.77M | 7.65B | 3.22% |
2023-06-29 | Capital International Investors | 43.15M | 5.81B | 2.44% |
2023-06-29 | Geode Capital Management, LLC | 34.95M | 4.71B | 1.98% |
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-06-29 | Vanguard Total Stock Market Index Fund | 55.03M | 7.41B | 3.12% |
2023-06-29 | Vanguard 500 Index Fund | 42.01M | 5.66B | 2.38% |
2023-05-30 | Fidelity 500 Index Fund | 19.79M | 2.73B | 1.12% |
2023-08-30 | SPDR S&P 500 ETF Trust | 19.43M | 2.86B | 1.10% |
2023-09-29 | American Mutual Fund Inc | 17.76M | 2.65B | 1.01% |
2023-08-30 | iShares Core S&P 500 ETF | 16.50M | 2.43B | 0.93% |
Dividend | Date |
---|---|
1.55 | 2024-04-12 |
1.55 | 2024-01-15 |
1.55 | 2024-01-12 |
1.48 | 2023-10-12 |
1.48 | 2023-07-14 |
1.48 | 2023-07-13 |
-
why down though ? just doesn’t
make sense to me why so volatile -
-
$ABBVEngage Nicely With Professional System Via Trading Investments Accurate Signal Pattern Valid Strategies Helpful Methods Growing Portfolio Drastically️IN-STA-GRAM..TESLA.LIVELYHOOD
-
ʙɪᴛᴄᴏɪɴ ɪs ᴀ ᴠᴇʀʏ ʜɪɢʜ-ʀɪsᴋ #ɪɴᴠᴇsᴛᴍᴇɴᴛ ʙᴇᴄᴀᴜsᴇ ɪᴛ's ᴀ ᴠᴏʟᴀᴛɪʟᴇ ᴀssᴇᴛ. ᴛʜᴀᴛ ᴍᴇᴀɴs ᴛʜᴀᴛ ʙɪᴛᴄᴏɪɴ ᴠᴀʟᴜᴇs ᴍᴀʏ ʀɪsᴇ ᴏʀ ғᴀʟʟ ᴅʀᴀᴍᴀᴛɪᴄᴀʟʟʏ ɪɴ ᴠᴀʟᴜᴇ ᴏᴠᴇʀ ᴀ ᴠᴇʀʏ sʜᴏʀᴛ ᴘᴇʀɪᴏᴅ—ᴇᴠᴇɴ ᴀs ϙᴜɪᴄᴋʟʏ ᴀs ᴀ ғᴇᴡ ʜᴏᴜʀs ᴏʀ ᴅᴀʏs....ʟɪᴋᴇ ᴀʟʟ ᴄʀʏᴘᴛᴏᴄᴜʀʀᴇɴᴄɪᴇs ᴀɴᴅ ᴀ ɢᴏᴏᴅ ᴍᴇɴᴛᴏʀ ᴡɪʟʟ ɢᴜɪᴅᴇ ʏᴏᴜ ᴛʜʀᴏᴜɢʜ ᴛʜɪs ᴛʜᴏᴜɢʜ ᴘᴇʀɪᴏᴅ ᴛᴏ ᴍᴀᴋᴇ ᴇᴠᴇɴ ᴡɪᴛʜ ᴛʜᴇ ᴄᴜʀʀᴇɴᴛ ᴅʀᴏᴘ ɪɴ ᴄʀʏᴘᴛᴏᴄᴜʀʀᴇɴᴄɪᴇs, ɪ sᴛɪʟʟ ᴛʜᴀɴᴋ ʏᴏᴜ ғᴏʀ ᴛʜᴇ ʙᴀʟᴀɴᴄᴇᴅ ғɪɴᴀɴᴄɪᴀʟ ᴀᴅᴠɪᴄᴇ. ɪ sᴛᴀʀᴛᴇᴅ ɪɴᴠᴇsᴛɪɴɢ ɪɴ sᴛᴏᴄᴋs ᴀɴᴅ ᴄʀʏᴘᴛᴏᴄᴜʀʀᴇɴᴄɪᴇs ᴡɪᴛʜ $1,000 ᴀɴᴅ sɪɴᴄᴇ ɪ'ᴠᴇ ʙᴇᴇɴ ғᴏʟʟᴏᴡɪɴɢ ʏᴏᴜ ᴀʟʀᴇᴀᴅʏ? ʟᴏʟ-ᴊᴏʙʟᴇss ᴄʟᴀɪᴍs ᴜᴘ ᴀʟʟ ᴛʜᴇ ʀɪɢʜᴛ ᴛʜɪɴɢs ᴛʜᴀᴛ sʜᴏᴡ ʜɪɢʜᴇʀ ʀᴀᴛᴇs ᴀʀᴇ ᴅᴏɪɴɢ ᴛʜᴇ ᴊᴏʙ ᴀɴᴅ ᴛʜᴇ ᴍᴀʀᴋᴇᴛ ɢᴏᴇs ᴜᴘ ɪɴғʟᴀᴛɪᴏɴ ᴡɪᴛ ᴛʜᴇ ʙᴇsᴛ ᴡᴀʏ ᴛᴏ ғɪɴᴅ ᴛʜᴀᴛ ʙᴀʟᴀɴᴄᴇ ʙᴇᴛᴡᴇᴇɴ sᴀᴠɪɴɢ.
ғ, ᴀ, ᴄ, ᴇ, ʙ, ᴏ, ᴏ, ᴋ ᴋᴀᴛᴀʀɪɴᴀ ᴊ ᴍᴀxᴡᴇʟʟ
ɪ,ɴ,s,ᴛ,ᴀ,ɢ,ʀ,ᴀ,ᴍ ᴋᴀᴛᴀʀɪɴᴀ_ᴊ_ᴍᴀxᴡᴇʟʟ -
$ABBV I can proudly say my broker is one of the best manager Karen J Adams in Crypto market, I invested $500 and I made $5,810 after 7days of trade. Message her to be your guidance about trading she is on What'sApp +𝟏𝟖𝟏𝟐𝟐𝟕𝟎𝟔𝟖𝟎𝟕
-
All thanks to Mrs. Karen J Adams that helped me achieve my dreams through her trading program, I made over $30,000 in duration of 4 days she's so excellent and amazing. Visit her on TELEGRAM ᏦᎪᎡᎬΝ Ꭻ ᎪᎠᎪᎷՏ or WhatsApp +❶❽❶❷❷❼⓿❻❽⓿❼
-
Buy low, sell high.
-
-
-
So who will abbv buy to make up for revenue loss that the 2 hopeful drugs failed to come through? How to fill that void?
-
-
-
Buy at 150-155
-
-
NFA Guys!!!! LOOK into ATER !!! Look at the facts, Numbers are lined up & we own float SI is above 40% , 100% utilization for 72 days, we own the float, CTB is high, we just need volume, SQUEEZE bound to happen Join ATER discord n let us know ur new.HODL!! SQUEEZE PLAY!!! Just need volume!! Lookup AnonFtheHF vids on youtube or
DO YOUR OWN DD IF YOU DONT BELIVE, SEE FOR YOURSELF!!!!
Just a BULL sticking it to SHORTS/HF. Love ya’ll!!!Peace out brothers!! Ticker: ATER
NFA
-
AbbVie Inc. (NYSE:ABBV) Shares Sold by Bahl & Gaynor Inc.
news.google.com • -
ABBV Stock Earnings: AbbVie Beats EPS, Beats Revenue for Q1 2024
news.google.com • -
Abbvie stock falls amid growing biosimilar competition
news.google.com • -
AbbVie Stock Dives Despite 'Firing On All Cylinders' In First Quarter
news.google.com • -
Why AbbVie Stock Stumbled Today Despite the Earnings Beat
news.google.com • -
ABBV Stock Earnings: AbbVie Beats EPS, Beats Revenue for Q1 2024
news.google.com • -
AbbVie Stock Falls As Company Warns of Continued Humira Sales Slump
investopedia.com • -
AbbVie (ABBV) Q1 2024 Earnings Call Transcript
news.google.com • -
AbbVie (ABBV) Q1 2024 Earnings Call Transcript
news.google.com • -
Interesting ABBV Put And Call Options For July 19th
news.google.com • -
ABBV Stock Earnings: AbbVie Beats EPS, Beats Revenue for Q1 2024
news.google.com • -
AbbVie Q1 report beats Street despite plunging Humira sales (NYSE:ABBV)
news.google.com • -
AbbVie Q1 report beats Street despite plunging Humira sales (NYSE:ABBV)
news.google.com • -
AbbVie off 3% despite quarterly beats, 2024 guidance raise
news.google.com • -
PCE In-Line to Warmer, Pre-Market Calms; ABBV Beats, XOM Misses
news.google.com • -
AbbVie (ABBV) Reports Q1 Earnings: What Key Metrics Have to Say
news.google.com • -
AbbVie (ABBV) Beats Q1 Earnings and Revenue Estimates
news.google.com • -
PCE In-Line to Warmer, Pre-Market Calms; ABBV Beats, XOM Misses
news.google.com • -
5 stocks to watch on Friday: XOM, CVX, ABBV and more
news.google.com • -
5 stocks to watch on Friday: XOM, CVX, ABBV and more
news.google.com • -
AbbVie (ABBV) Beats Q1 Earnings and Revenue Estimates
news.google.com • -
AbbVie (ABBV) Beats Q1 Earnings and Revenue Estimates
news.google.com • -
AbbVie (ABBV) Beats Q1 Earnings and Revenue Estimates
news.google.com • -
AbbVie (ABBV) Beats Q1 Earnings and Revenue Estimates
news.google.com • -
AbbVie (ABBV) Beats Q1 Earnings and Revenue Estimates
news.google.com • -
ABBV Stock Earnings: AbbVie Beats EPS, Beats Revenue for Q1 2024
news.google.com • -
AbbVie (ABBV) Outpaces Stock Market Gains: What You Should Know
news.google.com • -
What's in Store for These 5 Pharma Bigwigs in Q1 Earnings?
news.google.com • -
Dividend Growth Stars: 7 Stocks With 10-Year Double-Digit Rate Hikes
investorplace.com • -
ABBV (AbbVie) Book Value per Share
news.google.com • -
AbbVie (ABBV) to Report Q1 Earnings: What's in the Cards?
news.google.com • -
Dividend Aristocrats In Focus: AbbVie
news.google.com • -
20 Years To $300k? Building A $10,000 Dividend Portfolio From Scratch
seekingalpha.com • -
Steady Income, Steady Growth: 7 Blue-Chip Dividend Stocks to Buy Now
investorplace.com • -
Is AbbVie a Millionaire Maker?
fool.com • -
AbbVie: Bulletproof Fundamentals
seekingalpha.com • -
AbbVie: Despite The Run, Shares Still Look Attractive, Yielding 3.67%
seekingalpha.com • -
Wall Street Favorites: 3 Biotech Stocks With Strong Buy Ratings for April 2024
investorplace.com • -
AbbVie: Still Fits Buffett's 10x EBT Rule Well Despite Guidance Revision
seekingalpha.com • -
Passive Income Perfection: 7 Dividend Stocks to Generate $50,000 Per Year
investorplace.com • -
2 Strong Dividend Buys And 2 Sells For Q2 2024
seekingalpha.com • -
The 3 Best Stocks to Buy in April 2024
investorplace.com • -
10 Dividend Growth Stocks: March 2024
seekingalpha.com • -
AbbVie acquisition signals confidence in small-cap biotech sector's growth potential
proactiveinvestors.com • -
2 Top Dividend Stocks to Buy Hand Over Fist
fool.com • -
3 Must-Have Dividend Kings for a Steady Income Stream
investorplace.com • -
Trouble-Proof Dividend Darlings: 7 Stocks That Keep Paying No Matter What
investorplace.com • -
AbbVie: Comeback Expected After Humira Patent Expiration
seekingalpha.com • -
3 Unstoppable Mega-Cap Stocks That Every Investor Should Own in 2024
investorplace.com • -
Despite Humira's Challenges, AbbVie's Execution Makes It A Buy
seekingalpha.com • -
AbbVie: Strong Cash Flow Growth Fuels Dividend Growth
seekingalpha.com •